Related Experiment Video
Updated: Jan 22, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.9K
TRP Channels Expression Profile in Human End-Stage Heart Failure
Martin Dragún1, Andrea Gažová2, Ján Kyselovič3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, 83232 Bratislava, Slovakia.
Medicina (Kaunas, Lithuania)
|July 19, 2019
Summary
End-stage heart failure shows altered expression of transient receptor potential (TRP) channels in human heart muscle. This study systematically maps these changes, revealing specific TRP channel alterations in failing myocardium.
Area of Science:
- Cardiology
- Molecular Biology
- Physiology
Background:
- Transient receptor potential (TRP) channels are implicated in cardiac hypertrophy, but data from human studies are limited and conflicting.
- Previous research primarily utilized animal models, necessitating investigation in human failing myocardium.
Purpose of the Study:
- To systematically analyze the expression of TRP channels (TRPC, TRPM, TRPV) in human failing heart tissue.
- To identify specific TRP channel expression patterns associated with end-stage heart failure.
- To correlate TRP channel expression with clinical and functional parameters in heart failure patients.
Main Methods:
- Quantitative real-time PCR was used to measure mRNA levels of TRPC, TRPM, and TRPV channels.
- Left-ventricular myocardial tissue was obtained from heart transplant recipients (NYHA III-IV) and healthy donors.
- Clinical, functional, and biochemical data were analyzed to confirm heart failure diagnosis.
Main Results:
- Significant upregulation of TRPC1, TRPC5, TRPM4, and TRPM7 mRNA was observed in failing myocardium compared to controls.
- Decreased expression of TRPC4 and TRPV2 mRNA was detected in heart failure patients.
- TRP channel expression changes were independent of gender, clinical, or functional parameters, but TRPC1 correlated with MEF2c expression.
Conclusions:
- End-stage human heart failure is characterized by distinct alterations in TRP channel expression profiles.
- This study provides a comprehensive description of TRP channel expression in the failing human heart.
- Further research is needed to elucidate the role of TRP channels in early stages of cardiac hypertrophy and heart failure progression.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
01:17Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
01:27Heart Failure I: Introduction
723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
01:22Heart Failure VI: Adjunct Therapies
277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
01:22Heart Failure Drugs: Diuretics
824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
01:30Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227